Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

ArrestAD · 3-O-sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer’s neurodegeneration

H2020Status: CLOSED1 January 201731 May 2022EU funding €3,991,096Call H2020-FETOPEN-2016-2017

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimer’s disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure. Research in the field has long been refining classic concepts based on the aggregation of Aβ and tau through initial seeding and then spreading. Our vision is different and based on the demonstration that tau abnormal phosphorylation and aggregation is triggered by the interaction of tau with heparan sulfates internalized in neurons and circulating cells only in AD [UPEC R.1; P.1,2]. Based in this new concept, ArrestAD will establish links between AD genetics, disease hallmarks, and altered traffic and intracellular accumulation of heparan sulfates to generate new knowledge underpinning the development of new strategies for detection and treatment of AD. This will open to radically new technologies addressing two major objectives: 1) proving that specific and early diagnosis of AD is possible in circulating cells, and 2) demonstrating that a new class of drug candidates are able to preventing and/or arresting AD-neurodegeneration. To reach these objectives, ArrestAD brings together internationally recognized experts in AD clinics and diagnosis, in heparan sulfate biology, transcriptomics, interactomics, carbohydrate chemistry, enzymology, cell biology, animal experimentation with AD models, and a SME specialized in the development of diagnosis kits using circulating cells. The high-risk character of this joint science and technology research is offset by the multidisciplinary nature of the Consortium and the high socio-economic gain resulting from success. Based in this technology, we will build a diverse portfolio of future projects that will result in a long-term benefit for citizens, economy and society.

Consortium · 9 organisations

coordinator

UNIVERSITE PARIS XII VAL DE MARNE

FR · €1,267,361

participant

STICHTING RADBOUD UNIVERSITEIT

NL · €322,139

participant

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

FR · €383,540

participant

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM

NL · €78,486

participant

SCREENCELL

FR · €57,445

participant

THE UNIVERSITY OF LIVERPOOL

UK · €579,250

participant

INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK

PL · €518,125

participant

UNIVERSITAT AUTONOMA DE BARCELONA

ES · €394,875

participant

FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA

ES · €389,875

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.